Zobrazeno 1 - 10
of 179
pro vyhledávání: '"Elizabeth C, Smyth"'
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in loca
Externí odkaz:
https://doaj.org/article/36962004dc3c44ad98772c39a7baef6f
Autor:
Harriet C Baker, Elizabeth C Smyth
Publikováno v:
The Lancet. Healthy Longevity, Vol 3, Iss 6, Pp e372-e373 (2022)
Externí odkaz:
https://doaj.org/article/09cc54db27c54488bc8dd78a3c2d1445
Autor:
Elizabeth C Smyth
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Externí odkaz:
https://doaj.org/article/1ba36554427f497e82954cc23a8d4bab
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Immune checkpoint inhibition has transformed cancer treatment. For gastroesophageal cancer, this class of drugs have demonstrated durable responses and survival benefit in a subgroup of patients, resulting in regulatory approval. However, several rec
Externí odkaz:
https://doaj.org/article/da1606f43caa440dbb850fcda6b50299
Autor:
Constantinos Simillis, Beth Taylor, Ayesha Ahmad, Nikhil Lal, Thalia Afxentiou, Michael P. Powar, Elizabeth C. Smyth, Nicola S. Fearnhead, James Wheeler, Richard J. Davies
Publikováno v:
European Journal of Cancer. 172:237-251
The impact of body mass index (BMI) on long-term survival outcomes after colorectal cancer surgery is debated.A systematic literature review and meta-analysis was performed to compare long-term survival outcomes of patients of different BMI categorie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::098a34de34d00d4ef5dbb15b31231db5
https://doi.org/10.1016/j.ejca.2022.05.020
https://doi.org/10.1016/j.ejca.2022.05.020
Publikováno v:
Current Opinion in Oncology. 34:389-394
Metastatic oesophagogastric cancers carry a prognosis of generally less than 2 years despite current treatment. There has been recent excitement in the field focused on immune checkpoint inhibition though anti-PD-1 antibodies. In this article, we rev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a20cadb3f7d6dffb78a0929ecc40cb1
https://doi.org/10.1097/cco.0000000000000859
https://doi.org/10.1097/cco.0000000000000859
Autor:
Maria Alsina, Elizabeth C Smyth
Publikováno v:
ESMO Open, Vol 4, Iss 5 (2019)
Externí odkaz:
https://doaj.org/article/a9d552ce209e4b0c94e7ec2e951fe148
Autor:
Elizabeth C. Smyth, Markus Moehler
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Survival for patients with unresectable advanced or recurrent gastric cancer (GC) remains poor and the historical lack of evidence-based therapeutic options after second-line therapy is reflected in current clinical guidelines for this condition. Des
Externí odkaz:
https://doaj.org/article/8ef46a95c5684c37804fe0b6e34a0503
Autor:
Joe Yeong, Chong Boon Teo, Ryan Yong Kiat Tay, Benjamin Kye Jyn Tan, Yiong Huak Chan, Elizabeth C. Smyth, Raghav Sundar
Publikováno v:
Gastric Cancer. 25:1133-1135
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f499e86f703ebb41f17a8f045840d9f4
https://doi.org/10.1007/s10120-022-01343-4
https://doi.org/10.1007/s10120-022-01343-4
Autor:
Yiong Huak Chan, Joseph J. Zhao, Elizabeth C Smyth, Nicholas Syn, Chong Boon Teo, Yu Yang Soon, Dominic Wei Ting Yap, Raghav Sundar, Benjamin Kye Jyn Tan
Publikováno v:
Journal of Clinical Oncology. 40:392-402
PURPOSE The US Food and Drug Administration has granted regulatory approval for the use of nivolumab—an immune checkpoint inhibitor (ICI)—in the first-line treatment of advanced gastric or esophageal adenocarcinoma (GEAC), regardless of programme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4cc86f9a43cc844b8a52b86c00c2db4
https://doi.org/10.1200/jco.21.01862
https://doi.org/10.1200/jco.21.01862